220 related articles for article (PubMed ID: 34615706)
21. Molecular strategies to define HLA haplotype loss in microdissected tumor cells.
Ramal LM; Maleno I; Cabrera T; Collado A; Ferron A; Lopez-Nevot MA; Garrido F
Hum Immunol; 2000 Oct; 61(10):1001-12. PubMed ID: 11082513
[TBL] [Abstract][Full Text] [Related]
22. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract][Full Text] [Related]
23. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors.
Jiménez P; Cantón J; Collado A; Cabrera T; Serrano A; Real LM; García A; Ruiz-Cabello F; Garrido F
Int J Cancer; 1999 Sep; 83(1):91-7. PubMed ID: 10449614
[TBL] [Abstract][Full Text] [Related]
24. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.
Tian T; Ruan M; Yang W; Shui R
Oncotarget; 2016 Jul; 7(28):44395-44405. PubMed ID: 27323808
[TBL] [Abstract][Full Text] [Related]
26. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
Stecklein SR; Barlow W; Pusztai L; Timms K; Kennedy R; Logan GE; Seitz R; Badve S; Gökmen-Polar Y; Porter P; Linden H; Tripathy D; Hortobagyi GN; Godwin AK; Thompson A; Hayes DF; Sharma P
JCO Precis Oncol; 2023 Sep; 7():e2300197. PubMed ID: 37972336
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite instability in Japanese female patients with triple-negative breast cancer.
Kurata K; Kubo M; Kai M; Mori H; Kawaji H; Kaneshiro K; Yamada M; Nishimura R; Osako T; Arima N; Okido M; Oda Y; Nakamura M
Breast Cancer; 2020 May; 27(3):490-498. PubMed ID: 31907878
[TBL] [Abstract][Full Text] [Related]
28. The prevalence of HLA-I LOH in Chinese pan-cancer patients and genomic features of patients harboring HLA-I LOH.
Zhao J; Xiao X; Li Y; Gao X; Zhang X; Liu Z; Yi Y; Fu X; Wang H; Guan Y; Xia X; Zhang W; Huang J
Hum Mutat; 2021 Oct; 42(10):1254-1264. PubMed ID: 34245634
[TBL] [Abstract][Full Text] [Related]
29. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system.
Jordanova ES; Riemersma SA; Philippo K; Giphart-Gassler M; Schuuring E; Kluin PM
Genes Chromosomes Cancer; 2002 Sep; 35(1):38-48. PubMed ID: 12203788
[TBL] [Abstract][Full Text] [Related]
30. Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of
Garrido MA; Perea F; Vilchez JR; Rodríguez T; Anderson P; Garrido F; Ruiz-Cabello F; Aptsiauri N
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680201
[TBL] [Abstract][Full Text] [Related]
31. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
[TBL] [Abstract][Full Text] [Related]
32. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.
Ogino S; Nosho K; Irahara N; Shima K; Baba Y; Kirkner GJ; Meyerhardt JA; Fuchs CS
J Clin Oncol; 2009 Sep; 27(27):4591-8. PubMed ID: 19704056
[TBL] [Abstract][Full Text] [Related]
34. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
Yeong J; Lim JCT; Lee B; Li H; Chia N; Ong CCH; Lye WK; Putti TC; Dent R; Lim E; Thike AA; Tan PH; Iqbal J
Front Immunol; 2018; 9():1209. PubMed ID: 29899747
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability.
Hirata T; Yamamoto H; Taniguchi H; Horiuchi S; Oki M; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Apr; 211(5):516-523. PubMed ID: 17318812
[TBL] [Abstract][Full Text] [Related]
36. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells.
Honma M
Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360
[TBL] [Abstract][Full Text] [Related]
37. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
38. High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta2-microglobulin LOH analysis.
Koene GJ; Arts-Hilkes YH; van der Ven KJ; Rozemuller EH; Slootweg PJ; de Weger RA; Tilanus MG
Tissue Antigens; 2004 Oct; 64(4):452-61. PubMed ID: 15361122
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
